• Completed dosing in 2026 Animal Study #2 (GLP-1-A26-2) testing oral DehydraTECH formulations of retatrutide and amycretin.
• Study measures 24-hour pharmacokinetics, tolerability, and formulation performance across 18 arms, targeting potential new intellectual property.
• Program tests tablets versus capsules to assess stomach-led versus intestine-led absorption for next-generation GLP-1 peptide drugs.
• Also evaluates alternatives to SNAC, including sodium caprate, aiming to improve absorption and reduce nausea or gastrointestinal side effects.
• Self-sponsored study funded from existing corporate resources.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202606090925TNWSWRCACNPR_____1AdyFmE4Q) on June 09, 2026, and is solely responsible for the information contained therein.